🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Thyroid Carcinoma

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369NA1 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: individualized mRNA neoantigen vaccine (mRNA-0523-L001) MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC NCT07235566Phase 21 site📍 Shanghai Fudan University · Tests: MRG003 in combination with pucotenlimab Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer NCT06431620NA1 site📍 Nanjing Nanjing First Hospital, Nanjing Medical University · Tests: Recombinant Human Thyroid Stimulating Hormone RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer NCT06530316n/a1 site📍 Shanghai Fudan University · Tests: RET Inhibitor, Surgery A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer NCT06195228Phase 48 sites📍 Fuzhou📍 Zhengzhou📍 Wuhan Fudan University · Tests: dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibd… Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer NCT06482086Phase 21 site📍 Chengdu West China Hospital · Tests: Anlotinib, Lenvatinib, Sorafenib, Donafenib, Everolimus Adjuvant Radiotherapy in High Risk Locally Advanced DTC NCT06558981Phase 31 site📍 Shanghai Fudan University · Tests: Radiotherapy, radioiodine treatment Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194Phase 1, Phase 26 sites📍 Denver📍 Miami📍 Boston ModeX Therapeutics, An OPKO Health Company · Tests: MDX2001 Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment. NCT06507878n/a1 site📍 Houston M.D. Anderson Cancer Center Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer NCT07419932n/a1 site📍 Fuzhou Fujian Medical University · Tests: Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor, PD(L)-1 … Sacituzumab govitEcan in THYroid Cancers NCT06235216Phase 211 sites📍 Barcelona📍 Ferrol📍 Hospitalet de Llobregat (Barcelona) Grupo Espanol de Tumores Neuroendocrinos · Tests: Sacituzumab govitecan Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery NCT06959511Phase 24 sites📍 Ann Arbor📍 Cleveland📍 Houston M.D. Anderson Cancer Center · Tests: Zanzalintinib A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer NCT07225309NA2 sites📍 New York📍 Mexico City Memorial Sloan Kettering Cancer Center · Tests: Meaning-Centered Psychotherapy for Latinos /MCP-L Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management NCT04216732n/a2 sites📍 San Francisco📍 Houston M.D. Anderson Cancer Center · Tests: Blood Pressure Measurement, Questionnaire Administration EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study NCT07447089NA1 site📍 Milan Università Cattolica di Milano · Tests: EMDR-IGTP-OTS Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer NCT06970353Phase 21 site📍 Shanghai Fudan University · Tests: Tunlametinib, Tunlametinib+PD-1 mAb Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor NCT07433283Phase 1, Phase 29 sites📍 Beijing📍 Hunan📍 Chongqing Sichuan Enray Pharmaceutical Sciences Company · Tests: Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer NCT05837260n/a1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Sample collection only RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer NCT06524167n/a1 site📍 Shanghai Fudan University · Tests: adjuvant radiotherapy Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors NCT07704658Phase 42 sites📍 Logroño📍 Madrid Rigel Pharmaceuticals · Tests: Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT03175224Phase 235 sites📍 Los Angeles📍 Tampa📍 Boston Apollomics Inc. · Tests: APL-101 Oral Capsules Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer NCT06359847Phase 21 site📍 Beijing Beijing Scitech-Mq Pharmaceuticals Limited · Tests: ST-1898 tablets XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer NCT06959641Phase 22 sites📍 Torrance📍 Chicago Jochen Lorch · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment NCT06405217NA1 site📍 Nanjing Nanjing First Hospital, Nanjing Medical University · Tests: Recombinant Human Thyroid Stimulating Hormone Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma NCT05994365n/a3 sites📍 Beijing📍 Tianjin📍 Tianjin Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: Anlotinib Hydrochloride Capsule Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas NCT06863805n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: 4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer NCT07874321Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment) Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma NCT05830500Phase 419 sites📍 Hefei📍 Beijing📍 Lanzhou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: Anlotinib Hydrochloride Capsule A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma NCT06860971Phase 335 sites📍 Hefei📍 Beijing📍 Chongqing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: AL2846 Capsules, AL2846 Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy